γ-Aminobutyric acid (GABA) signalling in human pancreatic islets is altered in type 2 diabetes
- First Online:
- Cite this article as:
- Taneera, J., Jin, Z., Jin, Y. et al. Diabetologia (2012) 55: 1985. doi:10.1007/s00125-012-2548-7
- 1.2k Downloads
γ-Aminobutyric acid (GABA) is a signalling molecule in the interstitial space in pancreatic islets. We examined the expression and function of the GABA signalling system components in human pancreatic islets from normoglycaemic and type 2 diabetic individuals.
Expression of GABA signalling system components was studied by microarray, quantitative PCR analysis, immunohistochemistry and patch-clamp experiments on cells in intact islets. Hormone release was measured from intact islets.
The GABA signalling system was compromised in islets from type 2 diabetic individuals, where the expression of the genes encoding the α1, α2, β2 and β3 GABAA channel subunits was downregulated. GABA originating within the islets evoked tonic currents in the cells. The currents were enhanced by pentobarbital and inhibited by the GABAA receptor antagonist, SR95531. The effects of SR95531 on hormone release revealed that activation of GABAA channels (GABAA receptors) decreased both insulin and glucagon secretion. The GABAB receptor antagonist, CPG55845, increased insulin release in islets (16.7 mmol/l glucose) from normoglycaemic and type 2 diabetic individuals.
Interstitial GABA activates GABAA channels and GABAB receptors and effectively modulates hormone release in islets from type 2 diabetic and normoglycaemic individuals.
Keywordsγ-Aminobutyric acidGene expressionHuman isletsType 2 diabetes
γ-Aminobutyric acid (GABA) is an extracellular signal molecule in the pancreatic islet [1–6]. GAD catalyses the formation of GABA from glutamate in the beta cells where GABA is present in both the cytoplasm and vesicles [1, 6]. Once released, GABA is thought to act in an auto- and para-crine manner on the islet cells to modulate hormone secretion [7, 8]. The effective interstitial physiological concentration of GABA in islets is not known. Keeping the proper levels may be critical for balancing the insulin and glucagon secretion. Interstitial GABA may also have a role in maintaining beta cell mass [9, 10].
GABA activates GABAA receptors and the GABAB receptor in the plasma membrane of alpha, beta and delta cells [8, 11–14]. The GABAA receptors are pentameric ion channels (GABAA channels) and normally contain three types of subunit: 2αs, 2βs and a third type of subunit. To date, 19 different mammalian GABAA subunits (α1-6, β1-3, γ1-3, δ, ε, π, θ and ρ1-3) have been cloned [15, 16]. Evidence for the existence of a multitude of GABAA channel subtypes comes from pharmacological studies. It has been shown that, for example, benzodiazepine-site ligands can differentiate between GABAA channel subtypes based on the type of α and γ subunits in the channel complex . Studies with ligands such as GABA and general anaesthetics have further confirmed and extended the list of GABAA channel subtypes . The heterogeneity of channel subunits not only results in differential response to drugs but also in a range of physiological properties such as variable channel conductance and kinetics [16, 17]. The response to GABA can be further modulated by intracellular proteins and factors that are associated with the channel complex [16, 17]. In contrast, there is only one type of GABAB receptor, which is a G-protein-coupled receptor composed of two homologous subunits, GABABR1 and GABABR2 . The GABAB1 subunit binds GABA, whereas the GABAB2 subunit is responsible for Gi/o-protein-coupled activation .
The GABAA channels have been best studied in the brain and can be classified into two main groups, synaptic and extrasynaptic channels, based on their location on neurons and physiological and pharmacological characteristics [16, 17, 20]. Synaptic channels are located in the postsynaptic membrane, respond rapidly and are activated by millimolar concentrations of GABA, whereas extrasynaptic channels are located outside of synapses, are activated with a latency of minutes and are saturated by submicromolar GABA concentrations [17, 20]. In the islets, GABA is released by synaptic-like microvesicles , by exocytosis together with insulin from the large-dense core vesicles , by kiss-and-run exocytosis  or by a non-vesicular process [6, 21]. Only in the vicinity of the vesicular release site on the beta and delta cells can the GABA concentration be expected to be in the tens of micromolar to millimolar range [1, 8] and activate transient (phasic), synaptic-like GABAA currents. Elsewhere, the low interstitial concentrations of GABA may generate long-lasting (tonic) currents by activating extrasynaptic-like GABAA channels in the islet cells similar to that recorded in neurons . If GABA modulates the electrical activity of the islet cells, then the spatial and temporal relative concentration of GABA in the endocrine pancreas has the potential to modulate hormone secretion in the islets and thereby may contribute to the pathogenesis of type 2 diabetes if the GABA concentration fluctuations fall outside of the normal range . Recently, Braun et al showed that many of the 19 GABAA channel subunits are expressed in human pancreatic islets . Here we extend the search to profile the expression of the GABA signalling system in pancreatic islets obtained from individuals with or without type 2 diabetes. We demonstrate that the GABAA channel subunits, α1, α2, β2 and β3, are downregulated in islets from individuals with type 2 diabetes. We also show that the interstitial GABA concentration in intact human islets activates GABAA channel currents, which are increased by pentobarbital. Hormone secretion is altered in islets from individuals with type 2 diabetes but can be enhanced with GABAA and GABAB antagonists.
Islets from cadaver donors were provided by the Nordic Islet Transplantation Programme (www.nordicislets.org). Islets were obtained from 54 non-diabetic donors (25 female, 29 male; mean ± SD: age 59 ± 9 years, BMI 25.9 ± 3.5, HbA1c 5.5 ± 1.1% [37 ± 11 mmol/mol] and days of culture 3.5 ± 1.9) and nine type 2 diabetic donors (four female, five male; mean ± SD age 57 ± 4 years, BMI 28.5 ± 4.5, HbA1c 7.2 ± 1.1%, (55 ± 11 mmol/mol) and days of culture 3.3 ± 1.5). Purity of islets was measured by dithizone staining and varied from 57 ± 19% in the type 2 diabetic islets to 67 ± 17% in the non-diabetic islets (p = 0.15). We also tried to obtain an estimate of the contribution of exocrine and endocrine tissue by measuring expression of pancreatic lipase, α2 amylase and chymotrypsin 2, as markers of exocrine tissue, and somatostatin and glucagon, as markers of endocrine tissue (probes for insulin were not on the Affymetrix chip). Using this approach, we found that the contribution of endocrine tissue did not differ between non-diabetic and type 2 donors (72 ± 12% vs 68 ± 10%, p = 0.29). We also measured insulin content as a surrogate marker for beta cell mass in pancreatic islets from hyperglycaemic and normoglycaemic donors and observed only a modest insignificant decrease in insulin content in islets from hyperglycaemic vs normoglycaemic donors (4.8 ± 3.2 vs 5.6 ± 3.2; p = 0.4). To obtain a measure of the contribution of beta and alpha cells in hyperglycaemic and normoglycaemic individuals, we calculated the ratio between MafA, a beta cell marker, and MafB, an alpha cell marker; this ratio did not differ between hyperglycaemic and normoglycaemic donors (43 ± 13% vs 38 ± 12%, p = 0.1). Only hand-picked islet preparations were used for the hormone and electrophysiological experiments. The islets were cultured in CMRL 1066 (ICN Biomedicals, Costa Mesa, CA, USA) supplemented with 10 mmol/l HEPES, 2 mmol/l l-glutamine, 50 μg/ml gentamicin, 0.25 μg/ml Fungizone (Gibco, Gaithersburg, MD, USA), 20 μg/ml ciprofloxacin (Bayer Healthcare, Leverkusen, Germany) and 10 mmol/l nicotinamide at 37°C (5% CO2, vol./vol.) for 1–9 days before being used in experiments. All procedures were approved by the ethics committees at Uppsala and Lund Universities, and informed consent was obtained by appropriate measures from donors or their relatives.
Total RNA isolation
Total RNA was isolated from islets using the AllPrep DNA/RNA Mini Kit (Qiagen, Hilden, Germany). RNA concentration and quality were measured using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and Experion RNA gel chips (Bio-Rad, Hercules, CA, USA), respectively. RNA from sorted human pancreatic islet beta cells was kindly provided by Dr Cilio, Lund University.
Microarray gene expression
The microarrays were performed following the Affymetrix standard protocol as previously described  (see electronic supplementary material [ESM] text).
PCR (RT-qPCR) Gene expression profiling of the GABA signalling system components in human islet was performed on total RNA by RT-qPCR as previously described  (see ESM text). The primer sequences are shown in ESM Table 1.
Immunofluorescence staining of human islets was performed as previously described  (see ESM text).
Current recordings from cells in intact islets
All patch-clamp recordings were performed at room temperature (20–22°C) on intact islets. Drugs used were purchased from Sigma-Aldrich (Stockholm, Sweden) or Ascent Scientific (Weston-Super-Mare, UK). The positive modulator, pentobarbital, and the GABAA antagonist, SR95531, were dissolved in the extracellular solution. For the whole-cell voltage-clamp recordings, islets were perfused with an extracellular solution containing in mmol/l: 126 NaCl, 5.6 KCl, 2.6 CaCl2, 1.2 MgCl2 and 10 HEPES, pH 7.4 . The pipette solution contained in mmol/l: 125 CsCl, 30 CsOH, 10 EGTA, 1 MgCl2, 5 HEPES, pH 7.2. Recordings were made at the holding potential of −70 or −90 mV. The single-channel recordings were performed in the whole-cell patch-clamp configuration. Patch pipettes were made from borosilicate glass and had a resistance of 5–8 MΩ when filled with the pipette solution. Patch-clamp current recordings were carried out using an Axopatch 200B amplifier, filtered at 2 kHz, digitised online at 10 kHz using an analogue-to-digital converter and analysed with pClamp software (Molecular Devices, Sunnyvale, CA, USA).
Glucose-stimulated hormone secretion in human islets
Secretion of insulin or glucagon in human islets stimulated by glucose was measured by the standard protocol as previously described  (see ESM text).
Data are presented as mean±SEM. Differences in expression levels were analysed by Student’s t test or non-parametric Mann–Whitney test. Correlations were analysed using non-parametric Spearman’s tests. In all tests, p < 0.05 was considered significant. All statistical tests were performed using SPSS version 18.0 software (SPSS, Chicago, IL, USA) or Sigma Plot version 11 (Systat Software, San Jose, CA, USA).
Expression of genes encoding the GABA signalling system components in islets
A comprehensive expression profile of genes encoding proteins participating in the GABA signalling cascade in excitable cells was created using cDNA microarray from islets from 54 non-diabetic donors (ESM Fig. 1a, b). Of the genes encoding the GABAA channel subunits, the β3, γ2, δ, ε, π and ρ2 subunits were most prominently expressed in the islets (ESM Fig. 1a). High expression signals were also detected for GABARAP (GABA receptor-associated protein), radixin (RDX), the NKCC1 transporter (SLC12A2) and GAD65 (also known as GAD2) (ESM Fig. 1b).
Localisation of GABAA α1 and α2 channel subunit proteins in human pancreatic islets
Interstitial GABA activates GABAA channel currents in intact islets
Effects of GABAA channel and GABAB receptor antagonists on insulin and glucagon secretion in islets from individuals with or without type 2 diabetes
Figure 5a and c show that insulin secretion was increased at 1.0 mmol/l but significantly decreased at 16.7 mmol/l glucose in islets from individuals with type 2 diabetes compared with islets from normoglycaemic donors. At 1 mmol/l glucose, insulin secretion was increased by a factor of 1.6 in the islets from type 2 diabetic donors and was unaffected by either SR95531 (10 μmol/l, Fig. 5a) or CGP55845 (Fig. 5c). At 16.7 mmol/l glucose, insulin secretion in islets from the type 2 diabetic individuals was decreased by 60% (Fig. 5a), but could be increased about 1.5-fold with the GABAB receptor antagonist CPG55845 (Fig. 5c) in islets from both type 2 diabetic and normoglycaemic donors. As 10 μmol/l SR95531 may not completely inhibit very high-affinity GABAA channels, we examined in islets from two normoglycaemic individuals whether 100 μmol/l SR95531 had any effect on insulin secretion. In low (1 mmol/l) glucose, 100 μmol/l SR95531 significantly increased insulin secretion (1G + SR100 μmol/l: 0.20 ± 0.03 ng islet−1 h−1, n = 12 from two individuals; 1G: 0.14 ± 0.01 ng islet−1 h−1, n = 12 from four individuals, p < 0.05) to the level observed for type 2 diabetic individuals (0.23 ± 0.02 ng islet−1 h−1, n = 12 from three individuals), but failed to modulate insulin secretion in 16.7 mmol/l glucose (n = 12 from two individuals, data not shown).
Figure 5b and d show that glucagon secretion was only significantly increased in islets from type 2 diabetic individuals compared with normoglycaemic donors when the islets were exposed to 16.7 mmol/l glucose. Glucagon secretion could be enhanced with 10 μmol/l SR95331 (Fig. 5b) in islets exposed to either 1 or 16.7 mmol/l glucose, whereas CGP555845 (Fig. 5d) was without effect. SR95531 increased glucagon secretion at 1.0 and 16.7 mmol/l glucose by a factor of 1.3 and 1.5, respectively, in islets from type 2 diabetic donors, and a factor of 1.4 and 1.9, respectively, in islets from normoglycaemic donors. The somewhat reduced effect of 10 μmol/l SR95531 on islets from type 2 diabetic individuals may be due to the fact that these islets exhibited increased basal glucagon secretion compared with the normoglycaemic donors. The GABAB receptor antagonist, CGP55845, did not modulate glucagon secretion at either low or high glucose concentrations (Fig. 5d). Together these results demonstrate regulation of hormone release by the GABAA channels and GABAB receptors.
We further examined whether the mRNA expression of GABAA channel subunits α1 and α2 in islets correlated with the HbA1c or insulin secretion of donors. Interestingly, expression of the GABAA channel subunits, α1 and α2, in islets correlated negatively with the HbA1c level of donors (Fig. 5e, f), and α2, but not α1, correlated positively with insulin secretion stimulated with 16.7 mmol/l glucose (Fig. 5e, f).
Our results show an active role for the GABA signalling system in human pancreatic hormone release. Interstitial GABA released from pancreatic beta cells evokes GABA-generated currents in intact human islets by activating GABAA channels expressed in alpha and beta cells. The currents can be enhanced by the GABAA channel modulator, pentobarbital, and blocked by the specific GABAA antagonist, SR95531. The α1, α2, β2 and β3 GABAA channel subunit genes are downregulated in islets from type 2 diabetic individuals, whereas other components of the GABA signalling system are not affected. In islets from type 2 diabetic and normoglycaemic individuals, the GABAB receptor antagonist, CPPG55845, increased insulin release at 16.7 mmol/l glucose, whereas the GABAA channel antagonist, SR95531, increased glucagon release in both 1 and 16.7 mmol/l glucose.
Eighteen of 19 possible GABAA channel subunit genes were expressed in the islets, with the highest expression levels detected for the α1, α2, β3, γ2, π and ρ2 subunits. The results are in good agreement with the results of Braun et al . Immunostaining of islets confirmed the presence of α1 and α2 subunits in both the alpha and beta cells. The GABAA channels contain two αs, two βs and a third type of subunit in the channel complex. In islets, γ2, π or ρ2 could each be the third type of subunit in the pentameric channel, but would confer vastly different pharmacological properties on the channel . Intriguingly, the high expression of π and ρ2 subunit genes seen in human islets is very different from the low and restricted distribution in the brain [16, 26].
It is likely that a number of different subtypes of GABAA channels are expressed in the islets and that they differ in their sensitivity to GABA and other drugs . Whether the different single-channel conductances we recorded in this study are related to different GABAA channel subtypes or activation of a specific GABAA channel subtype by different concentrations of GABA remains to be determined [20, 27].
Glucose modulated GABAA channel gene expression is in agreement with previous reports , but, in contrast with mice, stimulation with high glucose concentration reduced the α2 GABAA channel subunit mRNA level in human islets. The glucose effect on expression was even stronger in islets from type 2 diabetic individuals, in whom not only α2 but also α1, β2 and β3 GABAA channel subunit expression was decreased compared with islets from normoglycaemic donors. In islets from type 2 diabetic and normoglycaemic individuals, we further compared gene expression of proteins that might modify the function of the GABA signalling system in the islets [17, 28]. These proteins included: (1) the GABAB receptor subunits; (2) the intracellular proteins, gephyrin and radixin, involved in plasma membrane clustering of GABAA channels; (3) GABARAP and HAP1, which take part in transport or recycling of the channels; (4) GAD65 and GAD67, which make GABA from glutamate; (5) GABA transporters (GAT1-3, BGT1), which transport GABA over the cell plasma membrane; and (6) transporters such as NKCC1 and KCC2, which determine the intracellular chloride concentration and thereby determine whether opening of the GABAA channels will cause depolarisation or hyperpolarisation of the cells. None of these proteins was differentially expressed in islets from non-diabetic or type 2 diabetic individuals.
It is well established that GABA can activate GABAA channels in pancreatic islets, but so far it has not been shown that the interstitial GABA concentration that exists within the islets is sufficient to activate the native channels [8, 12]. In recent years, evidence has emerged that extrasynaptic-like GABAA channels can be supersensitive to GABA, being activated by GABA concentrations in the picomolar to nanomolar range [20, 27]. Activation of the channels induces long-lasting (tonic) currents in neurons that modulate the cellular excitability [17, 29, 30]. In this study of intact human islets, interstitial GABA generated tonic currents in the cells. As no GABA was added, the GABA must have originated from cells within the islets. Furthermore, since the GABA-activated current was enhanced by pentobarbital, the interstitial GABA concentration must have been sub-saturating . Whether the reduced level of GABAA channel subunits, the decreased extracellular GABA, or both resulted in the reduced tonic current in the islets from the type 2 diabetic donors remains to be determined. Expression levels for the GABA transporters were low in the islets. In the brain, these transporters are essential for removing GABA from the synapse to avoid inactivation of the GABAA channels , but may not be needed in the islets, as small molecules diffuse down their concentration gradient and enter the blood in the highly vascularised islets.
At low (1 mmol/l) glucose, basal GABA inhibits insulin secretion by activating GABAA channels expressed in the beta cells. The finding that a saturating concentration (100 μmol/l) of the antagonist, SR95531, was required to increase the insulin release is consistent with either very high-affinity GABAA channels and/or higher local GABA concentrations in the vicinity of beta cells. How the inhibition comes about may be related to decreased open probability of Ca2+ channels by subthreshold depolarisations of the membrane potential for channel activation  or a general effect of voltage-dependent inactivation of channels involved in action potential firing . At 16.7 mmol/l glucose, the GABAB antagonist CPG55845 increased insulin release by a factor of 1.5 in islets from both normoglycaemic and type 2 diabetic individuals. These results indicate that the mechanism by which GABAB receptors modulate insulin secretion was intact in islets from type 2 diabetic individuals. They are also in agreement with the unchanged expression levels of GABAB receptor subunits in islets from type 2 diabetic donors.
The GABA signalling system is compromised in pancreatic islets from type 2 diabetic individuals. The α2 GABAA channel subunit is already downregulated in islets from hyperglycaemic individuals, and, as the disease progresses to type 2 diabetes, expression of the α1, β2 and β3 GABAA channel subunit genes also decreases. The GABA released within the islets normally activates GABAA channels and the GABAB receptor, which modulate insulin and glucagon release. The GABA signalling system is an integral part of a system in human islets maintaining glucose homeostasis. Characterising the functional and pharmacological properties of the GABAA channel subtypes expressed in alpha and beta cells may reveal new specific targets for drugs aimed at modulating hormone release.
Human pancreatic islets were obtained from The Nordic Network for Clinical Islet Transplantation, supported by the Swedish National Strategic Research Initiative EXODIAB (Excellence of Diabetes Research in Sweden) and the Juvenile Diabetes Research Foundation. We thank the Swedish Research Council, Swedish Diabetes Research Foundation, The Ernfors Foundation and EXODIAB for financial support. Z. Jin held a postdoctoral fellowship sponsored by EXODIAB and the Swedish Association for Medical Research (SSMF), E. Renström is a Senior Researcher at SRC, and L. Groop is a recipient of a European Research Council Advanced Researcher Award.
Duality of interest
The authors declare that there is no duality of interest associated with this manuscript.
JT, ZJ, YJ, SJM, EZ, SL, AS and OK implemented the research, interpreted results, contributed conceptually to manuscript revisions. JT, ZJ, YJ, ER, LG and BB designed experiments, interpreted results, and wrote the manuscript. All the authors approved the final manuscript.
This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.